EDSS 4-7, Multiple Sclerosis
Conditions
Brief summary
The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment
Interventions
DRUGFampyra
The will be given as per normal patient treatment plan
Sponsors
Vestre Viken Hospital Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients who according to the compound's Norwegian prescription guidelines are deemed eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS 4-7. They do not need a past history of optic neuritis, cognitive failure, fatigue or difficulties micturating.
Exclusion criteria
MS patients with contraindications to the compound according to the prescription guidelines. Patients who have been exposed to Fampyra in the past Patients with an MS attack within last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change from baseline in visual evoked potential after 2 weeks and 3 months | 5 months |
Countries
Norway
Outcome results
None listed